Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Direct Payment

$120,000.00

The Impact of Financial and Time Toxicity of Systemic Therapy in Patients with Cancer Enrolled in Clinical Trials

EF 2025-26

Résumé
Cancer treatments like chemotherapy, immunotherapy, and targeted therapies save lives, and some patients join clinical trials to access new treatments. While trials can offer hope, they can also be demanding. Patients may face extra costs for visits, travel, housing, or lost income, and spend significant time attending appointments or completing study requirements. These financial and time burdens can affect quality of life, decision-making, and access to care. Yet, these issues are not well studied, especially in Canada. My PhD research aims to measure these burdens for patients in cancer clinical trials. I first conducted three reviews as part of my thesis. One examined all FDA-approved cancer drugs and showed the number of trials has increased over time, meaning more patients may face extra burdens. Another review found that trial participants in the US spend about $300 per month on direct medical costs and $800 on indirect costs like travel or lost wages-about 50% more than patients not in trials. A third review showed that patients spend an average of 7.6 days each month on healthcare visits while in trials, double the time of patients receiving standard care. These reviews highlighted gaps: most studies were US-based, used different methods, and often looked back in time rather than measuring in real life. To fill these gaps, I am leading a study in Toronto. Patients in cancer trials will complete monthly surveys about costs, and detailed charts will track how much time they spend on healthcare and trial activities. This is the first study in Canada to measure both costs and time using standardized tools. The findings will help patients make informed choices about trial participation, guide trial design to reduce unnecessary burdens, and support policies for fairer access to trials. In the long term, this research aims to make clinical trials more patient-friendly, helping Canadians benefit from new cancer treatments without undue financial or time strain.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
539229
Name
Chow Ronald
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Health systems / services
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
The Impact of Financial and Time Toxicity of Systemic Therapy in Patients with Cancer Enrolled in Clinical Trials
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Adverse Effects; Clinical Trials; Financial Toxicity; Oncology; Time Toxicity
Abstract
Cancer treatments like chemotherapy, immunotherapy, and targeted therapies save lives, and some patients join clinical trials to access new treatments. While trials can offer hope, they can also be demanding. Patients may face extra costs for visits, travel, housing, or lost income, and spend significant time attending appointments or completing study requirements. These financial and time burdens can affect quality of life, decision-making, and access to care. Yet, these issues are not well studied, especially in Canada. My PhD research aims to measure these burdens for patients in cancer clinical trials. I first conducted three reviews as part of my thesis. One examined all FDA-approved cancer drugs and showed the number of trials has increased over time, meaning more patients may face extra burdens. Another review found that trial participants in the US spend about $300 per month on direct medical costs and $800 on indirect costs like travel or lost wages-about 50% more than patients not in trials. A third review showed that patients spend an average of 7.6 days each month on healthcare visits while in trials, double the time of patients receiving standard care. These reviews highlighted gaps: most studies were US-based, used different methods, and often looked back in time rather than measuring in real life. To fill these gaps, I am leading a study in Toronto. Patients in cancer trials will complete monthly surveys about costs, and detailed charts will track how much time they spend on healthcare and trial activities. This is the first study in Canada to measure both costs and time using standardized tools. The findings will help patients make informed choices about trial participation, guide trial design to reduce unnecessary burdens, and support policies for fairer access to trials. In the long term, this research aims to make clinical trials more patient-friendly, helping Canadians benefit from new cancer treatments without undue financial or time strain.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chow, Ronald
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~